These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

614 related items for PubMed ID: 33891379

  • 1. Bimekizumab versus Adalimumab in Plaque Psoriasis.
    Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, Langley RG, Vanvoorden V, De Cuyper D, Cioffi C, Peterson L, Cross N, Reich K.
    N Engl J Med; 2021 Jul 08; 385(2):130-141. PubMed ID: 33891379
    [Abstract] [Full Text] [Related]

  • 2. Bimekizumab versus Secukinumab in Plaque Psoriasis.
    Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, Paul C, De Cuyper D, Vanvoorden V, Madden C, Cioffi C, Peterson L, Blauvelt A.
    N Engl J Med; 2021 Jul 08; 385(2):142-152. PubMed ID: 33891380
    [Abstract] [Full Text] [Related]

  • 3. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M.
    Lancet; 2021 Feb 06; 397(10273):487-498. PubMed ID: 33549193
    [Abstract] [Full Text] [Related]

  • 4. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A.
    Lancet; 2021 Feb 06; 397(10273):475-486. PubMed ID: 33549192
    [Abstract] [Full Text] [Related]

  • 5. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
    Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, Cioffi C, Blauvelt A.
    J Am Acad Dermatol; 2018 Aug 06; 79(2):277-286.e10. PubMed ID: 29609013
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
    Thaçi D, Vender R, de Rie MA, Conrad C, Pariser DM, Strober B, Vanvoorden V, Wang M, Madden C, de Cuyper D, Kimball AB.
    Br J Dermatol; 2023 Jan 23; 188(1):22-31. PubMed ID: 36689515
    [Abstract] [Full Text] [Related]

  • 7. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
    Kokolakis G, Warren RB, Strober B, Blauvelt A, Puig L, Morita A, Gooderham M, Körber A, Vanvoorden V, Wang M, de Cuyper D, Madden C, Nunez Gomez N, Lebwohl M.
    Br J Dermatol; 2023 Feb 22; 188(3):330-340. PubMed ID: 36751950
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, Garg A, Gottlieb AB, Szepietowski JC, Bechara FG, Giamarellos-Bourboulis EJ, Fujita H, Rolleri R, Joshi P, Dokhe P, Muller E, Peterson L, Madden C, Bari M, Zouboulis CC.
    Lancet; 2024 Jun 08; 403(10443):2504-2519. PubMed ID: 38795716
    [Abstract] [Full Text] [Related]

  • 9. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K.
    N Engl J Med; 2015 Jul 09; 373(2):136-44. PubMed ID: 26154787
    [Abstract] [Full Text] [Related]

  • 10. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
    Blauvelt A, Papp KA, Merola JF, Gottlieb AB, Cross N, Madden C, Wang M, Cioffi C, Griffiths CEM.
    J Am Acad Dermatol; 2020 Nov 09; 83(5):1367-1374. PubMed ID: 32473974
    [Abstract] [Full Text] [Related]

  • 11. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A.
    Lancet; 2019 Sep 07; 394(10201):831-839. PubMed ID: 31402114
    [Abstract] [Full Text] [Related]

  • 12. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
    Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C.
    Lancet; 2019 Aug 17; 394(10198):576-586. PubMed ID: 31280967
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain PD, Landells I, Hoeger P, Kotkin C, Unnebrink K, Seyger M, Williams D.
    Lancet; 2017 Jul 01; 390(10089):40-49. PubMed ID: 28478975
    [Abstract] [Full Text] [Related]

  • 14. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
    McInnes IB, Asahina A, Coates LC, Landewé R, Merola JF, Ritchlin CT, Tanaka Y, Gossec L, Gottlieb AB, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Mease PJ.
    Lancet; 2023 Jan 07; 401(10370):25-37. PubMed ID: 36493791
    [Abstract] [Full Text] [Related]

  • 15. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Papp KA, Weinberg MA, Morris A, Reich K.
    Lancet; 2021 Apr 24; 397(10284):1564-1575. PubMed ID: 33894834
    [Abstract] [Full Text] [Related]

  • 16. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.
    Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, Samsonov MY, Fleischmann RM, CREDO2 Group.
    N Engl J Med; 2022 Aug 25; 387(8):715-726. PubMed ID: 36001712
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar 25; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
    Glatt S, Jemec GBE, Forman S, Sayed C, Schmieder G, Weisman J, Rolleri R, Seegobin S, Baeten D, Ionescu L, Zouboulis CC, Shaw S.
    JAMA Dermatol; 2021 Nov 01; 157(11):1279-1288. PubMed ID: 34406364
    [Abstract] [Full Text] [Related]

  • 19. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
    Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S.
    N Engl J Med; 2012 Mar 29; 366(13):1190-9. PubMed ID: 22455413
    [Abstract] [Full Text] [Related]

  • 20. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
    Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL, UNCOVER-1 Study Group, UNCOVER-2 Study Group, UNCOVER-3 Study Group.
    N Engl J Med; 2016 Jul 28; 375(4):345-56. PubMed ID: 27299809
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.